comparemela.com

Latest Breaking News On - Affamed therapeutics ltd - Page 1 : comparemela.com

AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD

/PRNewswire/ AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical,.

Hong kongDayao zhaoHanmi pharmaceuticalsAffamed therapeutics ltdChina national medical products administrationDrug administrationAllegro ophthalmicHanmi pharmaceutical co ltdAmed therapeuticsNational medical products administrationClinical trial applicationIntermediate dry age related macular degenerationAffamed therapeuticsGreater chinaIntermediate drySpecial protocol assessment

AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL

/PRNewswire/ AffaMed Technologies ("AffaMed"), a joint venture established between AffaMed Therapeutics and SIFI S.p.A., today announced the completion of.

Yi luChan yiOphthalmic research instituteHospital of fudan universityMed technologiesAffamed therapeuticsRegistrational clinical trialExtended depth of focusFudan universityChina registrational clinicalGeneral managerAffamed technologiesGreater chinaAmed therapeuticsAffamed therapeutics ltd

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

/PRNewswire/ AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in.

United statesDayao zhaoEli lillyInternational burden of migraine studyCompany eli lillyAffamed therapeutics ltdMainland chinaAmed therapeuticsNational medical products administrationGreater chinaAffamed therapeuticsPain headacheInternational burdenMigraine studyGlobal burdenDisease study

vimarsana © 2020. All Rights Reserved.